glp 1 agonist shortage GLP-1 weight loss drugs leave users low on key nutrients, study finds Addressing the Shortage of GLP-1

Professional society guidelines now recommend GLP therapy for cardiovascular risk reduction in patients with type 2 diabetes and established cardiovascular disease or multiple cardiac risk factors

Eur J Heart Fail 19(1):6977

initiated a Phase 3 clinical trial for its investigational GLP-1 agonist compound MariTide, targeting obesity and cardiometabolic comorbidities

Diz-Chaves, Y

Additionally, in a humanfactors study involving 41 participants completing approximately 20 key tasks aligned with the USFDAs guidance for drugdevice combination products, the Obeda pen demonstrated noninferior userperformance outcomes compared with the innovator pen

The ACCORD Study Group